CStone Pharmaceuticals
Jason Yang is a physician-scientist and senior executive with 25+ years of biomedical research and biopharmaceutical R&D experience in oncology, form discovery, and translational medicine to clinical development.
He served as SVP and Head of Clinical Development at BeiGene, built BeiGene's clinical team and led the clinical development of 4 oncology assets from Phase I to pivotal trials including the first China-developed anti-PD-1 mAb.
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.